Synta Pharmaceuticals Corporation

University of Texas System

Immunesensor Therapeutics, Inc.

Beth Israel Deaconess Medical Center, Inc.

Children's Medical Center Corporation

Emory University

Shionogi Bioresearch Corporation

Healthall Laboratory, Inc.

Other

Kava Pharmaceuticals, Inc.

Nutriomix, Inc.

Shiongi Bioresearch Corp.

Lijun Sun

Shoujun Chen

Keizo Koya

Mitsunori Ono

Weiwen Ying

Zachary Demko

Jun Jiang

Hao Li

Elena Kostik

Teresa Przewloka

Zhi-Qiang Xia

Dinesh U Chimmanamada

Shijie Zhang

Yumiko Wada

David James

Zhijian Chen

Chuo Chen

Noriaki Tatsuta

Heping Shi

Howard P Ng

Yaming Wu

Christopher Borella

Zhenjian Du

Yu Xie

Kevin Paul Foley

Qi Wei

Takayo Inoue

Teresa Kowalczyk-Przewloka

Dan Zhou

Junghyun Chae

Shuzhen Qin

Jian Qiu

Youtong Wu

Guiqing Liang

Boyu Zhong

Jiaxi Wu

Farid Vaghefi

Elliot L Chaikof

Junyi Zhang

Chih-Yi Yu

Matt Tschantz

Mei Zhang

Jing Li

Stefan M Schweizer

Zhiqiang Xia

Sylvia Holden

Wojciech Wrona

Mats Harald Holmqvist

Huiling Tan

Jerome Mahiou

Natalie Alysia Dales

Bruce R Zetter

Joseph A Burlison

Minghu Song

Chi-Wan Lee

Joanna Dziewiszek

Yuniko Wada

Wenli Ding

Yuanwei Dai

Xueliang Tao

Jun Y Choi

Kun Ping Lu

Xiao Zhen Zhou

Nha Huu Vo

Shuo Wei

Gary Bohnert

Aristidis Veves

Qinglin Che

Timothy Korbut

Zhi Qiang Xia

Keizo Kova

Rashu Seth Bhargava

Xiao-Dong Li

M Ono

K Koya

Joel McCleary

Elena Kostic

Hulling Tan

Michelle Lynn Hall

Barbara Wegiel

Teresa Kowalczyk-Prezewloka

Teresa Kowalcyzk-Przewloka

The present disclosure relates to, among other things, antibody-drug conjugates comprising a STING agonist cyclic di-nucleotide conjugated to an antibody, preparation methods therefor, and uses therefor.

Antibody-sting agonist conjugates and their use in immunotherapy

A treatment for reducing glucose bioaccessibility can include providing a superabsorbent material that includes a porous network structure formed from a mixture of a plurality of water soluble polysaccharides that are not chemically crosslinked together. The superabsorbent material can be administered to a subject in an effective amount to reduce glucose bioaccessibility in the subject. In some aspects, the treatment for reducing glucose bioaccessibility with the superabsorbent material retains a substantially unaltered fatty acid bioaccessibility and/or retains a substantially unaltered protein bioaccessibility.

Modulation of glucose bioaccessibility with superabsorbent materials

The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

Quinoline cGAS antagonist compounds

Provided are compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, tautomers, isotopically labeled derivatives, polymorphs, and prodrugs thereof, wherein X-X, R, R, R, n, and Ring A are as defined herein. The compounds may be aryl hydrocarbon receptor agonists or partial aryl hydrocarbon receptor agonists. Also provided are pharmaceutical compositions comprising a compound of Formula (I) and methods of using such compounds for treating diseases and conditions related to the activity of an aryl hydrocarbon receptor, such as, for example, inflammatory diseases, autoimmune diseases, metabolic disorders, and proliferative diseases.

Aryl hydrocarbon receptor modulators and uses thereof

Disclosed are novel compounds of Formula I that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

cGAS antagonist compounds

A treatment for obesity can include: providing a superabsorbent material that includes a porous network structure formed from a mixture of a plurality of water soluble polysaccharides that are not chemically crosslinked together; and administering the superabsorbent material to a subject in an effective amount to provide a treatment for obesity in the subject. The treatment can include at least one of: reducing weight of the subject; reducing rate of weight gain in the subject; or increasing rate of weight loss in the subject. The treatment of obesity can include at least one of: reducing caloric intake into the subject; reducing caloric absorption by the gut of the subject; absorbing caloric material from the gut of the subject into the superabsorbent material; or increasing transfer of caloric material from bloodstream into gut.

Treatment for obesity with superabsorbent materials

Methods for reducing cholesterol in a subject can include: providing a superabsorbent material that includes a porous network structure formed from a mixture of a plurality of water soluble polysaccharides that are not chemically crosslinked together; and administering the superabsorbent material to a subject in an effective amount to reduce cholesterol in the subject. The reduction of cholesterol includes at least one of: reducing total cholesterol of the subject; reducing a rate of total cholesterol increase in the subject; or increasing a rate of total cholesterol decrease in the subject. The reduction of cholesterol includes at least one of: reducing cholesterol intake into the subject; reducing cholesterol absorption by the gut of the subject; or absorbing cholesterol material from the gut of the subject into the superabsorbent material. The reduction of cholesterol is by reduction of low-density-lipoprotein cholesterol or high-density-lipoprotein cholesterol.

Methods for reducing cholesterol with superabsorbent materials

Provided are superabsorbent materials composed of one or more water-soluble polysaccharides, such as gelling polysaccharides and gelling-compatible polysaccharides, and one or more insoluble fibers. The disclosed superabsorbent materials have a porous network structure and highly stable gelling properties as well as high absorption ratio and volume expansion capacity upon hydration or rehydration. Also provided are methods for preparing such superabsorbent materials and uses thereof.

Superabsorbent materials and methods of making the same

The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating and/or preventing proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

Compounds for treating proliferative diseases

Provided are compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, tautomers, isotopically labeled derivatives, polymorphs, and prodrugs thereof, wherein X-X, R, R, R, n, and Ring A are as defined herein. The compounds may be aryl hydrocarbon receptor agonists or partial aryl hydrocarbon receptor agonists. Also provided are pharmaceutical compositions comprising a compound of Formula (I) and methods of using such compounds for treating diseases and conditions related to the activity of an aryl hydrocarbon receptor, such as, for example, inflammatory diseases, autoimmune diseases, metabolic disorders, and proliferative diseases. 

CGAS antagonist compounds

Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 2'3-cGAMP, 2&#x2032;2-cGAMP, 3&#x2032;2&#x2032;-cGAMP and 3&#x2032;3&#x2032;-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies, and diagnostics.

Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway

Growing community of inventors

Harvard, MA, United States of America

Lijun Sun